ACLX241220P75000
- 0.75
- 0.000.00%
Arcellx Newsroom
Buy Rating for Arcellx Inc. Based on Promising Efficacy and Safety of BCMA CAR-T Therapy in IMMagine-1 Study
Morgan Stanley Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $111
Truist Financial Initiates Arcellx(ACLX.US) With Buy Rating
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $111 to $122
Arcellx Is Maintained at Buy by UBS
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $133
Arcellx Price Target Maintained With a $115.00/Share by HC Wainwright & Co.
Arcellx Analyst Ratings
Arcellx Inc (ACLX) Gets a Buy From Stifel Nicolaus
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Arcellx Inc (ACLX)
Piper Sandler Maintains Arcellx(ACLX.US) With Buy Rating, Raises Target Price to $115
TD Cowen Maintains Arcellx(ACLX.US) With Buy Rating
Needham Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $105
Arcellx Inc's Anito-cel Therapy Shows Promising Efficacy and Safety, Analysts Reaffirm Buy Rating
Needham Reiterates Buy on Arcellx, Maintains $105 Price Target
Arcellx Analyst Ratings
Barclays Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $115
Barclays Initiates Arcellx(ACLX.US) With Buy Rating, Announces Target Price $115
Scotiabank Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $133
Stifel Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $122